Reduction of bcl-2 in T cells during immunosuppressive therapy in patients with severe juvenile onset systemic lupus erythematosus

Clin Immunol. 1999 Oct;93(1):59-64. doi: 10.1006/clim.1999.4765.

Abstract

Overexpression of bcl-2 protein has been observed in the cytoplasm of T lymphocytes from adults with systemic lupus erythematosus (SLE). The aims of our study were to investigate the distribution of bcl-2 in T and B cells from patients affected with juvenile onset SLE (JSLE) and to monitor the modification of bcl-2 expression under immunosuppressive therapy. Thirty-two JSLE patients entered the study; 45 pathological and 16 healthy subjects were studied as controls. In SLE patients the disease activity was assessed using SLE disease activity index score. Bcl-2 expression was evaluated by cytofluorimetry. PCR analysis of t(14,18) translocation was performed from genomic DNA isolated from peripheral blood mononuclear cells. An increased bcl-2 expression both on cytoplasm and on cell surface of circulating T lymphocytes in JSLE patients with active disease was found. A variation, under pharmacological treatment, of protein expression during the course of the disease was observed. PCR analyses demonstrated that 14, 18 translocation was not associated with bcl-2 overexpression. Our data show a strong correlation between bcl-2 protein expression and disease activity and suggest an alteration of apoptotic regulation in JSLE patients.

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Child
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Leukocytes, Mononuclear / chemistry
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / epidemiology*
  • Male
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • T-Lymphocytes / chemistry*

Substances

  • Immunosuppressive Agents
  • Proto-Oncogene Proteins c-bcl-2